Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 664-672

  Mori, T ^a   Boyd, M R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIAL PROTEIN; CD4 ANTIGEN; CYANOVIRIN N; GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOPRECIPITATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TARGET CELL; VIRUS CELL INTERACTION;

ANTI-HIV AGENTS; ANTIGENS, CD4; BACTERIAL PROTEINS; BINDING SITES; CARRIER PROTEINS; FLOW CYTOMETRY; HIV; HIV ENVELOPE PROTEIN GP120; HUMANS; PRECIPITIN TESTS; RECEPTORS, CXCR4; TUMOR CELLS, CULTURED;

EID: 0035112229     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.664-672.2001     Document Type: Article

References (38)

1. Identification of the residues in human CD4 critical for the binding of HIV
2. Structural characterization of a cross-reactive idiotype shared by monoclonal antibodies specific for the human CD4 molecule
3. Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro
4. HIV entry and tropism. When one receptor is not enough
5. Solution structure of cyanovirin-N, a potent HIV-inactivating protein
6. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development
7. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization
8. A large array of human monoclonal antibodies to type 1 human immunodeficieney virus from combinatorial libraries of asymptomatic seropositive individuals
9. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
10. Multiple antiviral activities of cyanovirin-N: Blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses
11. Identification of CXCR4 domains that support coreceptor and chemokine receptor functions
12. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4
13. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120
14. Isolation, primary sequence determination, and disulfide bond structure of cyanovirin-N, an anti-HIV (human immunodeficiency virus) protein from the cyanobacterium Nostoc ellipsosporum
15. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor
16. HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors
17. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein
18. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
19. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines
20. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding
21. CD4-independent binding of SlY gp120 to rhesus CCR5
22. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans
23. Antigenic variation in gp120s from molecular clones of HIV-1 LAI
24. Co-receptors for HIV-1 entry
25. Analysis of sequence requirements for biological activity of cyanovirin-N, a potent HIV (human immunodeficiency virus)-inactivating protein
26. Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells
27. Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium
28. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity
29. CXCR4 is required by a nonprimate lentivirus: Heterologous expression of feline immunodeficiency virus in human, rodent, and feline cells
30. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
31. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon g120-CD4 binding
32. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5
33. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
34. Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization
35. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses
36. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5
37. The antigenic structure of the HIV gp120 envelope glycoprotein
38. Crystal structure of cyanovirin-N, a potent HIV-inactivating protein, shows unexpected domain swapping